Drug Trial Radar · NCT06767800
A Clinical Trial Evaluating TQB2102 for Injection in Combination With Behmosubaisumab/Payamprolizumab With or Without Chemotherapy in Unresectable Locally Advanced, Recurrent, or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastroesophageal Adenocarcinoma
Last checked: Nov 19, 2026Latest source record: Jul 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
204
Planned (sponsor's estimate)
Start
Nov 21, 2024
Primary completion
Sep 2026
Study completion Sep 2027
Sponsor
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 10, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
TQB2102 for injection is a novel antibody-coupled drug (ADC) that enhances binding to tumor cell surface HER2 proteins by simultaneously targeting the two non-overlapping epitopes of the HER2 protein, Endothelial Cell Dysfunction 2 (ECD2) and Endothelial Cell Dysfunction 4 (ECD4), increasing HER2 internalization, and then down-regulating the tumor cell surface HER2 proteins more effectively, and doubly blocking the HER2 signaling, to achieve the effects of trastuzumab and Pertuzumab alone and in combination. This is a Phase II study to evaluate the efficacy and safety of TQB2102 for injection in combination with Benmelstobart Injection /Penpulimab Injection ± chemotherapy in patients with unresectable locally advanced, recurrent or metastatic HER2-positive gastroesophageal adenocarcinoma
Conditions
- Gastroesophageal Adenocarcinoma
Interventions
TQB2102 for injection (7.5 mg) +Benmelstobart+ChemotherapyDrug
TQB2102 for injection is an antibody-coupled drug Benmelstobart is a Programmed cell death -Ligand 1 (PD-L1) Antibody
TQB2102 for injection (6 mg/7.5 mg) +Benmelstobart+ChemotherapyDrug
TQB2102 for injection is an antibody-coupled drug Benmelstobart is a PD-L1 Antibody
TQB2102 for injection (6 mg/7.5 mg) +Penpulimab+ChemotherapyDrug
TQB2102 for injection is an antibody-coupled drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR)Time frame: Through study completion, an average of 1 year
Locations
39 sites in 1 country. Site status is shown where the registry gives one.
Fuyang Cancer Hospital
Fuyang, Anhui, China · Not yet recruiting
Lu'an People's Hospital
Lu'an, Anhui, China · Not yet recruiting
Maanshan People's Hospital
Maanshan, Anhui, China · Recruiting
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China · Not yet recruiting
The first affiliated hospital of chongqing medical university
Chongqing, Chongqing Municipality, China · Not yet recruiting
Fujian Cancer Hospital
Fuzhou, Fujian, China · Not yet recruiting
Gansu Prouincial Cancer Hospital
Lanzhou, Gansu, China · Not yet recruiting
Gansu Wuwei Tumour Hospital
Wuwei, Gansu, China · Not yet recruiting
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China · Not yet recruiting
Nanfang Hospital
Guangzhou, Guangdong, China · Not yet recruiting
Jiangmen Central Hospital
Jiangmen, Guangdong, China · Not yet recruiting
Meizhou People's Hospital
Meizhou, Guangdong, China · Not yet recruiting
The Second Affiliated Hospital of Guilin Medical College
Guilin, Guangxi, China · Not yet recruiting
Guangxi Medical University Cancer Hospital
Nanning, Guangxi, China · Not yet recruiting
The first affiliated hospital of hainan medical university
Haikou, Hainan, China · Not yet recruiting
The Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, China · Not yet recruiting
Tangshan People's Hospital
Tangshan, Hebei, China · Not yet recruiting
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China · Not yet recruiting
Anyang Cancer Hospital
Anyang, Henan, China · Not yet recruiting
The 1st Affiliated Hospital of He'nan University of Science and Technology
Luoyang, Henan, China · Not yet recruiting
Puyang Oilfield General Hospital
Puyang, Henan, China · Not yet recruiting
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China · Not yet recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China · Not yet recruiting
Xiangyang Central Hospital
Xiangyang, Hubei, China · Not yet recruiting
Hunan Cancer Hospital
Changsha, Hunan, China · Not yet recruiting
The Second Xiangya Hospital Of Central South University
Changsha, Hunan, China · Not yet recruiting
NanJing Drum Tower Hospital
Nanjing, Jiangsu, China · Not yet recruiting
Jiangning Hospital of Nanjing City
Nanjing, Jiangsu, China · Not yet recruiting
Northern Jiangsu People's Hospital
Yangzhou, Jiangsu, China · Not yet recruiting
Jilin Cancer Hospital
Changchun, Jilin, China · Not yet recruiting
Cancer Hospital of Shandong First Medical University
Jinan, Shandong, China · Not yet recruiting
Fudan university shanghai cancer center
Shanghai, Shanghai Municipality, China · Not yet recruiting
Renji Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China · Not yet recruiting
Shanxi Cancer hospital
Taiyuan, Shanxi, China · Not yet recruiting
The First Affiliated Hospital of Xi'an Jiao Tong University
Xi’an, Shanxi, China · Not yet recruiting
Nanchong Central Hospital
Nanchong, Sichuan, China · Not yet recruiting
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, China · Not yet recruiting
Xinjiang Medical University Affiliated Cancer Hospital
Ürümqi, Xinjiang, China · Not yet recruiting
Wenzhou Medical University Affiliated First Hospital
Wenzhou, Zhejiang, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.